{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-005782","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.091558+00:00","generated_at":"2026-06-23T23:21:37.520283+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PharmaCyte (PMCB) reaches cooperation deal with Iroquois; appoints five new independent directors","bullets":["Five prior directors resigned; five new directors appointed to reconstituted 7-member board effective Aug 15, 2022.","Iroquois, holding ~6.7% stake, gets two appointees (Schechter, Silverman); standstill until Sept 30, 2024 or later.","New independent directors: Allen, Farb, Stover join existing directors Waggoner and Abecassis.","New directors receive $12,500/quarter cash retainer, 334 shares, and option for 334 shares with five-year term.","Iroquois agreed to customary standstill, including voting and ownership limits (14.9% cap) through standstill period."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-005782","json":"https://secwatch.observer/filing/0001683168-22-005782.json","markdown":"https://secwatch.observer/filing/0001683168-22-005782.md","text":"https://secwatch.observer/filing/0001683168-22-005782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/pharmacyte_8k-081422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:21:37.520283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"080c6ce8bb","claim":"Farb was appointed as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"132f8c2aba","claim":"Dr. Matthias Löhr resigned as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"3275eb688d","claim":"Allen was appointed as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"37582dfccd","claim":"Stover was appointed as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"4f9d286bca","claim":"Dr. Tong resigned as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"8b7fd27b5d","claim":"Mr. Liquard resigned as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"9f27eb0b8c","claim":"Schechter was appointed as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"da50f973b2","claim":"Silverman was appointed as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"f4c1192a1e","claim":"Dr. Crabtree resigned as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"f6fe0ca4f2","claim":"Mr. Trujillo resigned as director at PharmaCyte Biotech, Inc..","evidence_excerpt":"effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}